- Presentations
- 3
- Markets
- 1
Yorvipath is a brand of Palopegteriparatide marketed by Ascendis Pharma Endocrinology, with 3 presentations listed and registered in United States. Each presentation below has its own page with packs, documents and availability for export supply from India.
- Active ingredient (INN)
- Palopegteriparatide
- Brand owner
- Ascendis Pharma Endocrinology
- Registered in
- United States
- Strengths and forms
- 168 mcg/0.56 mL injection, 294 mcg/0.98 mL injection, 420 mcg/1.4 mL injection
All presentations
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Yorvipath 168 mcg/0.56 mL injectionSubcutaneous Cold chain | Ascendis Pharma Endocrinology | US FDA | Available on request |
| Yorvipath 294 mcg/0.98 mL injectionSubcutaneous Cold chain | Ascendis Pharma Endocrinology | US FDA | Available on request |
| Yorvipath 420 mcg/1.4 mL injectionSubcutaneous Cold chain | Ascendis Pharma Endocrinology | US FDA | Available on request |
Brand names and trademarks belong to their owners and are used only to identify products.
Request Yorvipath
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.